Extraordinarily Fast Response to Low-Dose Sertraline in a Child with Severe Obsessive-Compulsive Disorder and High Functioning Serotonin Transporter Genotype

Grünblatt, Edna; Tschakarjan, Senop; Brezinka, Veronika; Walitza, Susanne

doi:10.1089/cap.2013.0064

Cited by 5 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Denys et al (2007) detected an association between response in venlafaxine-treated OCD patients with the S/L genotype, although they didn't find the association of 5-HT-TLPR with the paroxetine treatment response. There is a case report about a 7-year-old boy with severe early-onset OCD and high functioning serotonin transporter who respond extraordinarily fast to low-dose sertraline (25mg for two weeks) (Grünblatt et al, 2014). Finally an abstract was presented in the 12th annual pharmacogenetics in psychiatry meeting reported the association of three SNPs across SLC6A4 with paroxetine response (P= 0.0006-0.010) in 119 OCD patients treated with fluoxetine, fluvoxamine, sertraline, paroxetine and citalopram and clomipramine (Zhang et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Association of two specific haplotypes of serotonin transporter gene with fluvoxamine treatment outcomein Iranian patients with obsessive compulsive disorder

et al. 2021

View full text Add to dashboard Cite

Introduction: Converging lines of evidence indicate that serotonin transporter has a role in response to selective serotonin reuptake inhibitors pharmacotherapy in a variety of neuropsychiatric disorders. In the present study, the association of four functional loci of the serotonin transporter gene (SLC6A4) with fluvoxamine treatment outcome in Iranian patients with obsessive compulsive disorder (OCD) has been investigated. Methods: A total of 352 Iranian OCD patients were screened for the treatment outcome. Pharmacotherapy was defined as 12 weeks of treatment with fluvoxamine (150-300mg). Finally, 132 patients who had completed their treatment were assigned to three groups (responders, non-responders and refractory) and underwent genotyping for SLC6A4 variations (STin2, 5-HTTLPR, rs25531 and rs25532) employing PCR-RFLP. Results: Results showed no significant differences between different STin2, 5-HTTLPR/ rs25531 and rs25532 single locus genotype frequencies. However, significant associations of two SLC6A4 haplotypes with treatment response were detected. Conclusion: Detected association of two SLC6A4 haplotypes with response to fluvoxamine in OCD patients proposed that the research emphasis of OCD pharmacogenetic studies may be placed on haplotype association analyses in candidate genes. This may represent a significant advance over single-locus investigations as a way to understand the influence of genetic factors on drug response in OCD.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of two specific haplotypes of serotonin transporter gene with fluvoxamine treatment outcomein Iranian patients with obsessive compulsive disorder

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Currently, several pharmacogenetic approaches using hypothesis-free GWAS have been conducted into the association between candidate genes and drug response in OCD patients (Di Bella et al, 2002;Denys et al, 2007;Van Nieuwerburgh et al, 2009;Miguita et al, 2011;Grünblatt et al, 2014;Zai et al, 2014;Umehara et al, 2015;Mas et al, 2016;Qin et al, 2016;Umehara et al, 2016;Taj et al, 2018;Lisoway et al, 2018;Sina et al, 2018;Abdolhosseinzadeh et al, 2019a,b;Alizadeh et al, 2019). The candidate genes investigated belong to: (1) pharmacokinetic regulating genes, such as the CYP450 liver enzymes such as CYP2D6 and CYP2C19;…”

Section: Pharmacogeneticsmentioning

confidence: 99%

Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders

Fineberg

Hollander

Pallanti

et al. 2020

International Clinical Psychopharmacology

Self Cite

View full text Add to dashboard Cite

In this position statement, developed by The International College of Obsessive-Compulsive Spectrum Disorders, a group of international experts responds to recent developments in the evidence-based management of obsessive-compulsive disorder (OCD). The article presents those selected therapeutic advances judged to be of utmost relevance to the treatment of OCD, based on new and emerging evidence from clinical and translational science. Areas covered include refinement in the methods of clinical assessment, the importance of early intervention based on new staging models and the need to provide sustained well-being involving effective relapse prevention. The relative benefits of psychological, pharmacological and somatic treatments are reviewed and novel treatment strategies for difficult to treat OCD, including neurostimulation, as well as new areas for research such as problematic internet use, novel digital interventions, immunological therapies, pharmacogenetics and novel forms of psychotherapy are discussed.

show abstract

Zwangsstörungen

Wewetzer¹,

Walitza²

2016

Neuro-/Psychopharmaka Im Kindes- Und Jugendalter

View full text Add to dashboard Cite

Extraordinarily Fast Response to Low-Dose Sertraline in a Child with Severe Obsessive-Compulsive Disorder and High Functioning Serotonin Transporter Genotype

Abstract: Originally published at: Grünblatt, Edna; Tschakarjan, Senop; Brezinka, Veronika; Walitza, Susanne (2014). Extraordinarily fast response to low-dose sertraline in a child with severe obsessive-compulsive disorder and high functioning serotonin transporter genotype.

Cited by 5 publications

References 19 publications

Association of two specific haplotypes of serotonin transporter gene with fluvoxamine treatment outcomein Iranian patients with obsessive compulsive disorder

Association of two specific haplotypes of serotonin transporter gene with fluvoxamine treatment outcomein Iranian patients with obsessive compulsive disorder

Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders

Zwangsstörungen

Contact Info

Product

Resources

About